Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: Past, present and future

Expert Review of Anticancer Therapy

Volumn 7, Issue 4, 2007, Pages 477-487

  Sabharwal, Ami ^a   Kerr, David ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

5 fluorouracil; Bevacizumab; Capecitabine; Chemotherapy; Colorectalk cancer; Irinotecan oxaliplatin

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; LEVAMISOLE; MONOCLONAL ANTIBODY; OXALIPLATIN; PAZOPANIB; PELITINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB; VATALANIB;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG USE; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HAIR LOSS; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LIVER METASTASIS; LIVER SURGERY; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROGNOSIS; QUALITY OF LIFE; RECTUM CANCER; REVIEW; SKIN TOXICITY; STOMATITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FORECASTING; HUMANS; NEOPLASM STAGING;

EID: 34247617339     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.4.477     Document Type: Review

References (87)

1. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J. Clin. Oncol. 16(1), 301-308 (1998).
2. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 10(4), 250-261 (2005).
3. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol. 19(8), 2282-2292 (2001).
4. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol. 19(21), 4097-4106 (2001).
5. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138), 1407-1412 (1998).
6. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138), 1413-1418 (1998).
7. Rougier P, Lepere C. Second-line treatment of patients with metastatic colorectal cancer. Semin. Oncol. 32(6 Suppl. 9), S48-S54 (2005).
8. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209), 1041-1047 (2000).
9. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343(13), 905-914 (2000).
10. Kohne CH, van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J. Clin. Oncol. 23(22), 4856-4865 (2005).
11. Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU) folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Presented at: ASCO 2002, Orlando, FL, USA. 18-21 May. Am. Soc. Clin. Oncol. (2002) (Abstract 512).
12. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947 (2000).
13. Tewes M, Schleucher N, Achterrath W et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended Phase I study. Ann. Oncol. 14(9), 1442-1448 (2003).
14. Borner MM, Bernhard J, Dietrich D et al. A randomized Phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann. Oncol. 16(2), 282-288 (2005).
15. Hochster HS, Welles L, Hart L et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. J. Clin. Oncol. (2005) (Abstract 3515).
16. Sastre J, Massuti B, Tabernero JM et al. Preliminary results of a randomized Phase III trial of the TTD Group comparing capecitabine and oxaliplatin (CapeOx) vs. oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectai cancer (CRC). J. Clin. Oncol. (2005) 23, S16 (Abstract 3524).
17. Cassidy J, Clarke S, Diaz Rubio E et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2×2 factorial Phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann. Oncol. 17(Suppl. 9) (2006) (Abstract LBA3).
18. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004).
19. Rowland KM, Pitot HC, Sargent DJ et al. Results of 3rd line therapy on N9841: a randomized Phase III trial of oxaliplatin/ 5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy. J. Clin. Oncol. 23, S16 (2005) (Abstract 3519).
20. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol. 21(11), 2059-2069 (2003).
21. Rothenberg ML, Oza AM, Burger B et al. Final results of a Phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1011).
22. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
23. Sobrero A, Ackland S, Carrion RP et al. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. J. Clin. Oncol. 24, S18 (2006) (Abstract 3544).
24. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 23(15), 3502-3508 (2005).
25. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J. Clin. Oncol. 24, S18 (2006) (Abstract 3510).
26. Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Ontology Group (ECOG) study E3200. J. Clin. Oncol. 23, S16 (2005) (Abstract 2).
27. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
28. Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J. Clin. Oncol. 24, S18 (2006) (Abstract 3509).
29. Lal R, Dickson J, Cunningham D et al. A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J. Clin. Oncol. 22(15), 3023-3031 (2004).
30. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361(9356), 457-464 (2003).
31. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancera. GERCOR study. J. Clin. Oncol. 24(3), 394-400 (2006).
32. Maindrault-Goebel F, Lledo G, Chibaudel B et al. OPTIMOX2, a large randomized Phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. J. Clin. Oncol. 24, S18 (2006) (Abstract 3504).
33. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Registry of Hepatic Metastases. Surgery 103(3), 278-288 (1988).
34. Azoulay D, Castaing D, Smail A et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann. Surg. 231(4), 480-486 (2000).
35. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. 224(4), 509-520; discussion 520-502 (1996).
36. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann. Oncol. 14(Suppl. 2), 13-16 (2003).
37. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol. 10(6), 663-669 (1999).
38. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol. 16(8), 1311-1319 (2005).
39. Folprecht G, Lutz MP, Seufferlein T et al. Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC) - final results and pharmacokinetic data of a Phase I/IIa study. J. Clin. Oncol. 23, S16 (2005) (Abstract 3640).
40. Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J. Clin. Oncol. 23(36), 9243-9249 (2005).
41. Falcone A, Masi G, Murr R et al. Biweekly irinotecan, oxaliplatin, and infusional 5FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): results of a randomized, Phase III trial by the Gruppo Oncologico Nord Ovest (GONO). J. Clin. Oncol. 24, S18 (2006) (Abstract 227).
42. Meric F, Patt YZ, Curley SA et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann. Surg. Oncol. 7(7), 490-495 (2000).
43. Elias D, Lasser P, Rougier P et al. Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J. Am. Coll. Surg. 180(2), 213-219 (1995).
44. Kemeny N, Jarnagin W, Paty P et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J. Clin. Oncol. 23(22), 4888-4896 (2005).
45. Nordlinger B, Sorbye H, Debois M et al. Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized Phase III study 40983. J. Clin. Oncol. 23, S16 (2005) (Abstract 3528).
46. Aloia T, Sebagh M. Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J. Clin. Oncol. 24(31), 4983-4990 (2006).
47. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol. 24(13), 2065-2072 (2006).
48. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 259(24), 3571-3578 (1988).
49. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322(6), 352-358 (1990).
50. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345(8955), 939-944 (1995).
51. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J. Clin. Oncol. 15(1), 246-250 (1997).
52. Zaniboni A, Labianca R, Marsoni S et al. GIVIO-SITAC 01: a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma - long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon. Cancer 82(11), 2135-2144 (1998).
53. Haller DG, Catalano PJ, Macdonald JS et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J. Clin. Oncol. 23(34), 8671-8678 (2005).
54. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 355(9215), 1588-1596 (2000).
55. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J. Clin. Oncol. 16(1), 295-300 (1998).
56. Andre T, Colin P, Louver C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J. Clin. Oncol. 21(15), 2896-2903 (2003).
57. Benson AB 3rd. Adjuvant chemotherapy of stage III colon cancer. Semin. Oncol. 32(6 Suppl. 9), S74-S77 (2005).
58. Cassidy J, Scheithauer W, McKendrick J et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a Phase III trial. J. Clin. Oncol. 22, S14 (2004) (Abstract 3509).
59. Gramont A. Adjuvant therapy of stage II and III colon cancer. Semin. Oncol. 32(6 Suppl. 8), 11-14 (2005).
60. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343-2351 (2004).
61. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. J. Clin. Oncol. 23, S16 (2005) (Abstract 3501).
62. Wolmark N, Wieand HS, Kuebler JP, Colangelo L, Smith RE. A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. J. Clin. Oncol. 23, S16 (2005) (Abstract 3500).
63. Schmoll HJ, Tabernero J, Nowacki M et al. Final safety findings from a randomized Phase III trial of capecitabine + oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. J. Clin. Oncol. 24, S18 (2006) (Abstract 3569).
64. van Cutsem E, Labianca R, Hossfeld D et al. Randomized Phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). J. Clin. Oncol. 23, S16 (2005) (Abstract 8).
65. Ychou M, Raoul J, Douillard J et al. A Phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J. Clin. Oncol. 23, S16 (2005) (Abstract 3502).
66. Saltz LB, Niedzwiecki D, Hollis DR et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J. Clin. Oncol. 22, S14 (2004) (Abstract 3500).
67. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol. 17(5), 1349-1355 (1999).
68. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International multicentre pooled analysis of B2 colon cancer trials (IMPACT B2) investigators. J. Clin. Oncol. 17(5), 1356-1363 (1999).
69. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol. 22(10), 1797-1806 (2004).
70. Gray RG, Barnwell J, Hills R et al. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. J. Clin. Oncol. (2004) (Abstract 3501).
71. Lorenz M, Muller HH, Schramm H et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann. Surg. 228(6), 756-762 (1998).
72. Kemeny MM, Adak S, Gray B et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study. J. Clin. Oncol. 20(6), 1499-1505 (2002).
73. Kemeny N, Huang Y, Cohen AM et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N. Engl. J. Med. 341(27), 2039-2048 (1999).
74. Kusunoki M, Yanagi H, Noda M, Yoshikawa R, Yamamura T. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 89(6), 1228-1235 (2000).
75. Rudroff C, Altendorf-Hoffmann A, Stangl R, Scheele J. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after RO resection of colorectal liver metastases. Langenbecks Arch. Surg. 384(3), 243-249 (1999).
76. Tono T, Hasuike Y, Ohzato H, Takatsuka Y, Kikkawa N. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: a randomized study. Cancer 88(7), 1549-1556 (2000).
77. Clancy TE, Dixon E, Perlis R. Sutherland FR, Zinner MJ. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials. J. Gastrointest. Surg. 9(2), 198-206 (2005).
78. Hawkins N, Norrie M, Cheong K et al. CpG island merhylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122(5), 1376-1387 (2002).
79. Witzig TE, Loprinzi CL, Gonchoroff NJ et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68(4), 879-888 (1991).
80. Zhou W, Galizia G, Lieto E et al. Counting alleles reveals a connection between chromosome 18q loss and vascular invasion. Nat. Biotechnol. 19(1), 78-81 (2001).
81. Khan ZA, Jonas SK, Le-Marer N et al. p53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. Clin. Cancer Res. 6(9), 3499-3504 (2000).
82. Wang Y, Jatkoe T, Zhang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22(9), 1564-1571 (2004).
83. Linardou H, Murray S, Manoloukos M et al. The role of excision repair polymorphisin (XPD K751Q and ERCC1-118) in predicting response to oxaliplatin-based regimens in colorectal cancer patients: a Hellenic Cooperative Oncology Group Study. Ann. Oncol. 245 (2006) (Abstract 880P).
84. Kweekel DM, Gelderblom H, van der Straaten T, Punt CJ, Guchelaar H-J. UGT1A1*28 genotype and irinotecan dose adaptation in patients with metastatic colorectal cancer (MCRC) - a Dutch Colorectal Cancer Group (DCCG) study. Ann. Oncol. 45 (2006) (Abstract 882P).
85. Hecht JR, Trarbach T, Jaeger E et al. A randomized, double-blind, placebo-controlled, Phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J. Clin. Oncol. 23, S16 (2005) (Abstract 3).
86. Koehne C, Bajetta E, Lin E et al. Results of an interim analysis of a multinational randomized, double-blind, Phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J. Clin. Oncol. 24, S18 (2006) (Abstract 3508).
87. Arnold D, Peinert S, Voigt W, Schmoll HJ. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist 11(6), 602-611 (2006).